Evidence suggests that PPARγ overexpressioncan accelerate cancer progression, leading to interest in selectivePPARγ antagonists for cancer therapy.12 Additionally, its involvement in regulating neuroinflammation suggestspotential applications in neurodegenerative diseases such as amyotrophiclateral sclerosis (ALS) and Parkinson’s disease.12 Ongoing research into PPARγ modulationunderscores the importance of understanding ligand–receptorinteractions to develop safer and more effective drugs.13 The gene discussed is PPARG; the disease is cancer.